ArticlemAbs2025
A unified topology-based classification of SARS-CoV-2 RBD neutralizing antibodies systematizes affinity trends across variants.
Article in mAbs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Allosteric effects of CDR-H3 mutations modulate binding and neutralization of a conserved SARS-CoV-2 RBD-targeting antibody.Microbiology spectrum · 2026Article
- Localized Rigidification and Allosteric Modulation Mechanisms of SARS-CoV-2 Spike Neutralization by Class 3 and Class 4 Antibodies at Atomic Resolution: An Integrated Computational Study of Binding, Dynamics, and Allostery.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The receptor-binding domain (RBD) of the SARS-CoV-2 Spike protein, responsible for engaging the hACE2 receptor, is the principal target of neutralizing antibodies (NAb). To better understand how viral evolution undermines NAb protection, we present a comprehensive, topology-based classification derived from 544 NAbs and 60 nanobody-RBD complex structures. Five major NAb classes, each subdivided into two subclasses, were defined by binding zone, angle of approach, hACE2 competition, and hotspot usage. A systematic mapping of NAb-antigen contacts revealed 91 recurrent hotspot residues, some of which remain fully conserved across all Omicron variants. Leveraging > 2,300 experimentally dissociation constants spanning the Wuhan strain and Omicron lineages, we conducted a comparative affinity analysis across subclasses. NAbs in classes 1-3, which overlap the receptor-binding site, show progressive loss of affinity against Omicron, with many failing to bind recent subvariants due to emergent steric clashes and limited affinity maturation against the ancestral Wuhan RBD. Nonetheless, cases of Abs exhibiting resilience to viral drift have been documented. In contrast, classes 4 and 5 maintain high affinity regardless of their initial affinity for parental strains. Contemporary in-silico epitope predictors captured only ~40% of experimentally defined hotspots, highlighting the need for structure-guided approaches. By introducing a refined topological segmentation of the RBD grounded in previously described but unsystematized regions, our classification captures a broad diversity of NAb binding modes and provides an integrative structural framework that harmonizes prior classification schemes, its relationship with circulating variants, and highlights conserved epitope features relevant to broad-spectrum vaccine and therapeutic NAb design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.